Better Long-Term Buy: Eli Lilly or Viking Therapeutics?

Eli Lilly reported 2025 sales up 45% to more than $65 billion and net income of just under $21 billion, with multiple approved GLP-1 products and a newly approved weight-loss pill adding to growth. Viking Therapeutics' VK2735 remains a high-upside but riskier story, with injectable and oral versions showing patients losing up to 15% and 12% of weight in early trials and phase 3 underway. The article is bullish on both names, but highlights Lilly as the safer choice and Viking as a speculative takeover candidate if its drug wins approval.

Analysis

The market is still treating GLP-1 as a one-bet story, but the more interesting second-order setup is that the value is migrating from “who has a molecule” to “who controls distribution, manufacturing, and the next route of administration.” That is structurally favorable to LLY near term because it can monetize multiple shots on goal, but it also means the bar for sustaining multiple expansion gets higher: once a large cap is already priced as a category winner, incremental upside depends on surprise acceleration, not just execution.

VKTX is a classic timing asset rather than a fundamental compounder today. The stock’s torque is high because the market is effectively pricing the binary path to approval plus strategic optionality from an M&A takeout; that creates asymmetric upside, but also means any clinical delay, safety signal, or competitive read-through can compress the valuation quickly. The more subtle risk is that an approval does not automatically translate into durable economics if incumbents use scale, payer contracts, and supply chain leverage to mute launch velocity.

The underappreciated contrarian angle is that the current enthusiasm may be overstating the relevance of absolute efficacy and understating tolerability, adherence, and reimbursement friction. In obesity, the winner is often the product that remains on formulary and on therapy for 12–18 months, not the one with the best headline weight-loss number. That favors the incumbent platform more than the market narrative suggests, while still leaving room for a high-beta VKTX rerate if phase 3 data remain clean.

NVDA’s involvement is strategically important beyond the headline: it reinforces that AI is becoming a productivity lever for drug discovery, which should increase the advantage of firms with enough cash flow to fund data infrastructure. PFE’s role is more tactical—if the sector keeps paying for late-stage obesity assets, partnership and acquisition premiums may remain elevated, but they also cap upside for acquirers if they overpay into an arms race.

Key Decisions for Investors

• Stay long LLY as a quality compounder, but size it smaller than a pure growth name: 3-6 month upside is likely limited unless guidance inflects again; use pullbacks to add rather than chase at elevated multiples.
• For higher beta exposure, buy VKTX only as a defined-risk event position ahead of phase 3 milestones; prefer call spreads or a small equity starter because the payoff is binary and dilution risk remains meaningful.
• Pair trade: long LLY / short a basket of weaker GLP-1 challengers that lack late-stage de-risking. The thesis is that capital and payer access will concentrate around the incumbent platform while speculative names remain financing-dependent.
• If seeking M&A optionality, own VKTX only through catalysts with a hard stop on any safety disappointment; the risk/reward is attractive, but the correct holding period is months, not years.
• Watch PFE as a sentiment barometer for obesity M&A appetite; if takeover multiples keep expanding, rotate into names with cleaner balance sheets and later-stage assets rather than paying up for acquirers.